Company news
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) news
Kalaris Therapeutics, Inc. news releases on 6ix. Latest, Aug 31, 2026: Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Press releases & updates
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
August 31, 2026
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
July 20, 2026
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
July 17, 2026
Kalaris Appoints Laurie Keating to Board of Directors
July 6, 2026
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
June 22, 2026
Kalaris to Present at Clinical Trials at the Summit 2026
June 11, 2026
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
May 12, 2026
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
March 16, 2026
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
January 28, 2026
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
December 17, 2025
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
December 17, 2025
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
November 24, 2025
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 12, 2025
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
November 3, 2025
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
October 30, 2025
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
September 15, 2025
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
September 15, 2025
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 13, 2025
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
June 2, 2025
Kalaris to Participate at Stifel Ophthalmology Forum
May 23, 2025
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 14, 2025
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
April 4, 2025
Kalaris Announces Closing of Merger with AlloVir
March 18, 2025
Kalaris and AlloVir Announce Stockholder Approval of Merger
March 11, 2025
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
November 7, 2024
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
December 21, 2023
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
November 15, 2023
AlloVir Reports Second Quarter 2023 Financial Results
August 2, 2023
AlloVir Announces Proposed Public Offering of Common Stock
June 20, 2023
AlloVir Announces Pricing of Public Offering of Common Stock
June 20, 2023
AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)
June 4, 2023
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
May 15, 2023
AlloVir Reports First Quarter 2023 Financial Results
May 3, 2023
AlloVir to Present at the BofA Securities 2023 Health Care Conference
April 30, 2023
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
April 25, 2023
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
February 14, 2023
AlloVir to Participate in the SVB Securities Global Biopharma Conference
January 31, 2023
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
January 8, 2023
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 14, 2022
AlloVir Reports Third Quarter 2022 Financial Results
November 2, 2022
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 30, 2022
AlloVir Announces $126.6 Million Registered Direct Offering
July 26, 2022
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
June 6, 2022
AlloVir Appoints Shawn Tomasello to Its Board of Directors
March 30, 2022
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
February 9, 2022
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
January 4, 2022
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022